Be aware of link between diabetes and MGD
Diabetes is no island.
Doctors of optometry have long known that diabetes patients are at greater risk for such comorbidities as hypertension, obesity and dyslipidemia—plus diabetic retinopathy and glaucoma. Recent research underscores diabetes' link to meibomian gland dysfunction (MGD).
MGD, considered the leading cause of dry eye disease, is "a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion," according to the 2011 International Workshop on Meibomian Gland Dysfunction.
Researchers based in Colombia and Spain recently presented their findings via poster at the Association for Research in Vision and Ophthalmology meeting. In their study, they looked at the cases of 73 participants, including 37 with type 2 diabetes, with the remainder in a control group. Beyond the glands, which are located in the tarsal plate of the upper and lower eyelids, the researchers looked at participants' ocular surface and tear function. Participants also responded to two questionnaires.
The findings revealed that 71% of all study participants had MGD; 76% of the participants with diabetes had MGD; 67% of the control group had MGD. Symptoms of MGD were more severe in participants with diabetes.
Looking for MGD in diabetes patients
The study is consistent with similar studies, says Mile Brujic, O.D., who practices in Ohio and closely follows developments related to dry eye and MGD.
"It has been known that the prevalence of dry eye is greater in patients with diabetes," Dr. Brujic says. "MGD is one of the leading reasons for dry eye. This seems to correlate well with what we see in clinical practice."
Still, the study reinforces that doctors of optometry should be on the lookout for the link when patients present. In 2016, they diagnosed more than 320,000 cases of diabetic retinopathy in patients who did not know they had diabetes. Many people learn of their diabetes risks through a dilated, comprehensive eye examination from their doctor of optometry. And the sooner doctors of optometry can detect the biomarkers, the sooner they can educate their patients about managing their disease through diet, exercise and medication.
"With the diabetic patient, often times our primary concern is assessment of the retina for the presence of diabetic retinopathy," Dr. Brujic says. "We need to pay particular attention to the ocular surface and make appropriate recommendations to optimize ocular surface health when signs of MGD exist."
AOA series addresses concerns about myopia management
With the prevalence of myopia on the rise worldwide, an AOA webinar attempts to erase concern over barriers to providing myopia management. The webinar kicked off a three-event series focused on raising awareness of myopia management as a standard of care especially for children. Next is “Meet the Myopia Experts” on Saturday, June 24, at Optometry’s Meeting® 2023 in Washington, D.C.
AOA serving patients through research in optometry
For the fifth consecutive year, the AOA is sponsoring the Investigator Initiated Research Award. Investigators are invited to electronically submit proposals by July 1 for projects designed to increase knowledge through basic clinical and/or translational science relative to the continuum of eye and vision care. The AOA provides a maximum of $50,000 in direct costs for research conduct. Eric Ritchey, O.D., Ph.D., talks about his current research on low-level light therapy for patients with meibomian gland dysfunction, which can lead to dry eye disease.
Marijuana sensibilities changing fast: Are you ready for patients’ questions?
Public support for marijuana legalization has never been higher in the U.S., but evidence of its clinical utility in glaucoma care remains clouded at best.